Colonization of intervertebral discs by *Cutibacterium acnes* in patients with low back pain: protocol for an analytical study with microbiological, phenotypic, genotypic, and multiomic techniques

5 Vinícius Magno da Rocha¹, Carla Ormundo Gonçalves Ximenes Lima², Eliane de
6 Oliveira Ferreira²; Gabriel Corrêa de Farias³; Fábio César Sousa Nogueira⁴; Luis
7 Caetano Martha Antunes⁵; Keila Mara Cassiano⁶; Rossano Kepler Alvim Fiorelli¹

8 ¹Departamento de Cirurgia geral e especializada, Escola de Medicina, Universidade 9 Federal do Estado do Rio de Janeiro (UniRio), Rio de Janeiro- RJ, Brazil; ² Departamento de Microbiologia Médica, Institito de Microbiologia Paulo de Góes, 10 11 Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro-RJ, Brazil; 12 ³Departamento de Biologia Celular e Molecular, Fundação Oswaldo Cruz, Rio de Janeiro – RJ, Brazil; ⁴Instituto de Química, Universidade Federal do Rio de Janeiro 13 (UFRJ), Rio de Janeiro-RJ, Brazil; ⁵Centro de Desenvolvimento Tecnológico em 14 Saúde, Fundação Oswaldo Cruz, Rio de Janeiro – RJ, Brazil; ⁶Departamento de 15 Estatística, Instituto de Matemática, Universidade Federal Fluminense (UFF), Niterói-16 17 RJ, Brazil;

Correspondig author: Eliane de Oliveira Ferreira, Av. Carlos Chagas Filho, 373,
CCS, Bloco I, 2 andar, Laboratório de Biologia de Anaeróbios, Departamento de
Microbiologia Médica, UFRJ, Rio de Janeiro-RJ, Brasil. E-mail:
eliane_ferreirarj@micro.ufrj.br

 Keywords: Intervertebral discs; *Cutibacterium acnes*; low back pain; analytical study;
 multiomic techniques. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24 Abstract

25

26 Lumbar disc degeneration (LDD) and low back pain (LBP) are two conditions that are 27 closely related. Several studies have shown Cutibacterium acnes colonization of 28 degenerated discs, but whether and how these finding correlates with LBP is unknown. 29 A prospective study was planned to identify molecules present in lumbar intervertebral discs (LLIVD) colonized by C. acnes in patients with LDD and LBP and correlate them 30 31 with their clinical, radiological, and demographic profiles. The clinical manifestations, 32 risk factors, and demographic characteristics of participants undergoing surgical 33 microdiscectomy will be tracked. Samples will be isolated and pathogens found in 34 LLIVD will be characterized phenotypically and genotypically. Whole genome sequencing (WGS) of isolated species will be used to phylotype and detect genes 35 associated with virulence, resistance, and oxidative stress. Multiomic analyses of 36 37 LLIVD colonized and non-colonized will be carried out to explain not only the pathogen's role in LDD, but also its involvement in the pathophysiology of LBP. This 38 39 study was approved by the Institutional Review Board (CAAE 40 50077521.0.0000.5258). All patients who agree to participate in the study will sign an 41 informed consent form. Regardless of the study's findings, the results will be published in a peer-reviewed medical journal. Trials registration number NCT05090553; pre-42 results. 43

44 Introduction

LBP is a common complaint in the general population, and its incidence is about five times higher in patients with LDD and Modic endplate changes.(1,2) The link between these findings and the isolation of low virulence pathogens in LIVD has already been described in several studies, generating a lot of interest in the topic and promoting the bacterial hypothesis of LDD.(3–14)

50 Albert et al. reported 46% of positive cultures for anaerobes in 61 patients undergoing lumbar discectomy, of which 80% had Modic type 1 changes.(15) Other studies 51 52 corroborate these findings, with high identification rates for Cutibacterium acnes, an 53 anaerobic and aerotolerant pathogen that is bacillus-shaped, stained by the Gram 54 method, pleomorphic, non-spore-forming, and a biofilm producer.(11,16-20) Rollason et al. isolated strains of this bacterium from the LIVD of 64 patients, revealing the 55 56 presence of genotypic profiles distinct from those found in the skin, suggesting that specific variants would be related to LBP.(21) 57

Other authors believe that the presence of this pathogen in the LIVD of asymptomatic patients is due to contamination of the specimens during sampling and/or sample treatment in the laboratory environment. Carricajo et al. found positive cultures for *C. acnes* in only 3.4% of the discs from 54 patients, defending the possibility of contamination.(22) Rigal et al. also analyzed LIVD from 313 patients who underwent video-assisted retroperitoneal discectomy, with positive cultures for only six patients.(23)

These marked divergences in microbiological results cast doubt on the bacterial hypothesis of LDD and, consequently, raise questions about the possibility of

anaerobic pathogens acting as triggers or amplifiers of LBP. Urquhart et al. conducted
a systematic review of the literature on the subject and concluded that there is
evidence correlating the *C. acnes* isolation with Modic type 1 changes and LBP, but
there is a lack of studies producing substantial and irrefutable evidence.(24)

Despite the fact that considerable effort has already been expended in determining the presence of *C. acnes* in LIVD, there are still no standard isolation protocols for this pathogen from this clinical specimen. Furthermore, prior to the preparation of this manuscript, studies have shown no consistency in the collection and analysis techniques used, making comparison and reproducibility of results difficult.

76 Aware of this reality, Astur et al. proposed a protocol for a cohort study to identify C. 77 acnes from intervertebral discs.(25) Although valid, the initiative has two significant 78 limitations that should be highlighted. First, after collecting clinical specimens, their 79 immediate inoculation in a liquid medium is not foreseen in the operating room, which 80 increases the contact time of the samples with the aerobic environment and reduces the chances of microorganism recovery even with culture-specific techniques. Second, 81 82 the authors also highlight sonication (ultrasound waves to release bacteria from the 83 biofilm of surgical prostheses) of specimens for subsequent inoculation in automated 84 blood culture vials; however, this technique was originally described for pathogen 85 recovery from orthopedic prostheses rather than biological tissue(26) and, because 86 the sonication parameters used are not clear (time, power, and frequency), the 87 reproduction of results by other authors and the validation of this protocol is compromised. 88

89 Specific microbiological identification techniques, such as immediate inoculation of 90 specimens in liquid culture medium while still in the operating room, vortex¹ for sessile 91 cell recovery, incubation time extension in an anaerobic atmosphere with replication 92 every 72 h, and the use of Matrix-Assisted Laser Desorption Ionization Time of Flight Mass spectrometry - MALDI-TOF MS (Bruker Coorporation), and multiplex-touchdown 93 PCR² are strategies that assure reliable results regarding the presence of bacteria in 94 95 intervertebral discs (27,28), but they do not explain the pathways through which these microorganisms would participate in LDD and/or LBP. 96

97 Once LIVD colonization by C. acnes is confirmed using microbiological techniques, in the absence of clinical signs of infection, the main challenge is to understand the 98 99 implications of this finding for homeostasis of that microenvironment. Rajasekaran et 100 al. showed strong evidence of LIVD colonization by C. acnes using rDNA-16s PCR 101 and proteomic analyses (29). These authors discovered not only host defense 102 proteins, but also proteins associated with bacterial viability and proliferation. Although 103 these findings have demonstrated the active presence of C. acnes in intervertebral 104 discs, definitively ruling out the possibility of contamination, they do not necessarily 105 reflect the activity of the expressed proteins, which may remain inactive and without 106 interference in pain-generating pathways and/or the inflammatory response.

In this context, the combined use of proteomic and metabolomic techniques to analyze LIVD colonized by *C. acnes* would be more appropriate in order to assess the subclinical consequences of the colonization by this pathogen.(30) These techniques have already been used successfully to define molecular signatures in other clinical settings,(31–34) especially in chronic pain,(35–40) and can also provide integrative information on cell function at the molecular level about the role of *C. acnes* in LDD and LBP.(41–44)

115 Hypotheses and objectives

116 Our hypothesis is that LDD and LBP are related to LIVD colonization by *C. acnes*.

The primary goal of this study is to determine the incidence of LIVD colonization by
low virulent pathogens using specific sampling and culture techniques, as well as
phenotypic and genotypic techniques for microbiological characterization.

Other objectives of the study include: 1- assessing the possibility of clinical specimen contamination in positive cultures; 2- establishing a correlation between the presence of the pathogen and the clinical and radiological profile (Modic type 1 changes) of the study participants; 3- to outline a phylotypic profile of the most isolated *C. acnes* strains by bacterial WGS; and 4- identify a molecular profile for LDD and LBP in patients with positive cultures for *C. acnes* through proteomic and metabolomic techniques.

126 Justifications

127 Colonization of LIVD by *C. acnes* in patients with LDD supports the bacterial 128 hypothesis of LBP (4,8,29,45–47). The determination of a molecular profile for these 129 patients will not only contribute to a better understanding of the pathophysiological

basis of LBP associated with LDD (41–43), but it will also positively interfere in the
clinical management of this common condition, rationalizing its treatment and
optimizing its costs.

Previously studies looked at small groups of patients and did not follow standardized sampling and analysis methods.(15,24,48,49) This makes it difficult to value these findings and while they do suggest a correlation between *C. acnes* and LBP, the evidence is insufficient to explain how this bacterium could be involved in the process of LIVD degeneration and generation/amplification of LBP.

138 This is the first protocol to investigate the role of *C. acnes* in LIVD degeneration, 139 combinina isolation with culture techniques. phenotypic and aenotypic 140 characterization techniques; and genomic, proteomic, and metabolomic techniques. 141 In addition, the protocol proposes the clinical-radiological characterization of the 142 participants, blinding the researchers and controlling confounding variables, and following appropriate selection criteria and statistical planning to obtain significant 143 144 results.

145 Methods and Analysis

146This study protocol is registered with the Research Ethics Committee (REC) [CAAE:14750077521.0.0000.5258] of the Gaffrée and Guinle University Hospital (HUGG) and at148Clinicaltrials.govunderNCT05090553

149 (https://clinicaltrials.gov/ct2/results?term=NCT05090553).

150 Study Design

This analytical study will be performed at a single location (Spine Surgery Center of São Matheus Hospital (HSM) in collaboration with the Gaffrée Guinle University Hospital (HUGG) and Anaerobic Biology Laboratory of Paulo de Góes Microbiology Institute of the Universidade Federal do Rio de Janeiro (UFRJ).

The analyses will be performed sequentially, according to the surgical procedures carried out on the selected participants, taking 6 months after for their recruitment and ending 6 months after the surgical treatment of the last patient. Data from participants will be collected using a form designed specifically for this study.

159 **Population**

160 Participants included in the study must meet the selection criteria listed below.

161 Inclusion Criteria

162 The inclusion criteria for the study will be participants aged between 18 and 65 years; 163 both sexes; complaint of low back pain lasting more than 3 months; magnetic 164 resonance imaging findings of lumbar disc degeneration (LDD) performed less than 6 months before inclusion in the study; indication for open surgical treatment with 165 166 isolated microdiscectomy or associated with lumbar arthrodesis; failure of conservative treatment for at least 6 weeks and/or progressive neurological deficit; 167 168 agreement to follow all phases of the clinical investigation, having signed the informed 169 consent form (ICF) for participation in the study.

170 Exclusion Criteria

The exclusion criteria for the study will be a history of open lumbar spine surgery at any stage of life; chemotherapy or pulse therapy with corticoids; immune deficiency; previous intradiscal therapies (nucleotomy or discography); previous endoscopic surgery; history of spinal infection treated with antibiotics in the 6 months prior to inclusion in the study; use of antibiotics in the 2 months prior to the surgical procedure; incomplete research inclusion form; refusal to participate and/or sign the ICF.

177 Patient and Public involvement

178 Participant eligibility will be evaluated by the study researchers through a clinical 179 interview and imaging exams evaluation, according to the participants' interest and availability to participate in the study. If the patient agrees to take part in the study, the 180 181 predetermined selection criteria will be used to evaluate them. The researchers will 182 explain the details of the study and conduct a joint reading of the ICF. Questions about the study objectives, risks and benefits, stages, and research confidentiality will be 183 184 answered. A patient will only participate upon signing the ICF at this stage of the 185 research. A copy of this document will be given to the participant, another to the 186 responsible researcher, and a third will be attached to the medical record. After signing 187 the consent form, the patient will undergo an evaluation for demographic and clinical data collection and the forms developed for this purpose will be completed. If the 188 189 patient is unable to read and sign the written consent form, researchers will verbally explain the study details and the patient will orally provide consent in the presence of 190 191 a witness who will sign the consent form. The recruitment of participants will take place 192 over a 6-month period, until 120 individuals are included, aiming at a minimum number of 96 collections. 193

194 **Participant Allocation**

The participants will be operated by the same surgical team, and the surgical technique will be posterior discectomy followed by arthrodesis of the approached segment.

198 Blinding

The results of microbiological cultures or molecular analysis will not be disclosed neither to the patients nor to the surgeons. The radiologist who will review the imaging tests will also be blinded to patient data and laboratory results. The researcher who will be analyzing the pain and function scores will be blinded as well.

203 Withdrawal of a Study Participant

A participant will be removed from the study in cases of ICF withdrawal, death, recruitment failure identification, loss of post-surgical follow-up, or the presentation of clinical symptoms of infection, intense pain, fever without other infectious *foci*, increased erythrocyte sedimentation rate and/or C-reactive protein, leukocytosis, imaging tests compatible with spondylodiscitis, or any other condition that leads to blinding interruption.

The reason and circumstances of each participant's withdrawal from the study will be detailed. The data gathered until the patient is withdrawn from the study will be included in the final analysis.

213 Selection of Outcomes

214 **Primary Outcome**

The main objective of this study will be to determine the incidence of intervertebral disc colonization by *C. acnes* in patients with LBP and LDD. Positive cultures will be used to confirm colonization, followed by phenotypic and genotypic confirmation of the isolated pathogen by mass spectrometry (Biotyper) and rDNA-16s PCR analysis, respectively.

220 Secondary Outcomes

221 Low back pain

At the time of patient recruitment the Visual Numeric Scale (VNS)(50) will be used to assess LBP intensity and daily activity limitations. A 30% increase in baseline LBP in the first postoperative month will be considered clinically significant. The VNS and the visual analogue scale have a good correlation and are equally sensitive to quantifying postoperative pain.(51)

227 Quality of life

The validated Portuguese version of the EuroQol questionnaire (EQ-5D) will be used to assess the quality of life of colonized and non-colonized groups with and without Modic changes.(52) The EQ-5D is a self-administrated standardized instrument containing five items (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression).

233 Functionality

The functionality of the participants will be quantified through the validated Portuguese
version of the Oswestry Disability Index (ODI) for LBP.(53)

237 Host multiomic characteristics

238 Proteomic and metabolomic techniques will be used to examine disc and plasma 239 samples. The comparison of the group of molecules found in disc and plasma samples may contribute to the quantitative and qualitative identification of profiles using 240 241 peripheral blood that are associated with the presence of the pathogen in the 242 intervertebral disc. After processing the multiomic raw data using proper bioinformatics 243 tools, statistical techniques will be applied to analyze them against the clinical-244 radiological and microbiological profiles of the participants. We expect to provide a molecular signature relating the presence of *C. acnes*, LDD and LBP. 245

246 Adverse Effects

Failures related to surgical treatment, such as surgical wound infection, CSF leak, deep vein thrombosis, pain recurrence, or any other adverse events that may arise in the postoperative period, will be reported and considered in data analysis.

250 Sampling

The Schedule of enrolment, Interventions, and assessments is shown in Fig. 1. During anesthetic induction, intravenous antibiotic prophylaxis will be administered after patient admission to the operating room. Cefazolin at a dose of 1 g replicated every 4 h for the duration of the surgery will be used as an antimicrobial drug. The antibiotic prophylaxis regimen will end with skin closure and will not be extended for additional postoperative time (Fig 2).

257 This is the legend of Fig 2. Flowchart showing all stages of the study.

259

260 The clinical specimens collected will be:

261

- 1. Peripheral blood. A 10 mL aliquot will be obtained 30 min after the infusion of
- surgical antibiotic prophylaxis through upper limb venoclysis. This sample will be

placed in a tube containing clot activator for further separation of the serum, which,

in turn, will be stored at -80° C for further analysis.

266 2. Skin swab. After skin asepsis with 2% chlorhexidine gluconate degerming solution
267 and 0.5% chlorhexidine gluconate alcoholic solution, a swab will be collected from
268 the region where the surgical incision will be performed.

269 3. Intervertebral disc. Five fragments will be collected at each level approached 270 during surgery. A set of sterile surgical tweezers will be used exclusively for 271 collection, one for each tissue fragment collected. The forceps with tissue 272 fragment will be given to a member of the laboratory who will monitor the 273 procedure inside the operating room immediately after collection. Each fragment will be placed in a vial containing thioglycolate broth (Merck[®], Brazil) and 20 glass 274 275 beads. The vials will be labeled with the initials of the study participants and the 276 type of clinical specimen. After collection, the vials containing the clinical 277 specimens will be kept at room temperature (18°C to 22°C) and transported in a 278 specific case to the laboratory within a maximum period of 2 h.

4. Muscle–ligament tissue. Before obtaining the LIVD fragments, five fragments of
 muscle–ligament tissue adjacent to the collected disc will be collected. The same
 collection and initial cooling precautions used for the disc fragments will be
 followed when collecting the adjacent tissue.

283 Laboratory Analysis

284 Cultures

The skin swabs will be opened only in a laboratory setting. Samples will be seeded on 285 blood agar plates (5% defibrinated sheep blood; blood agar base, 40 g/L; agar, 5 g/L) 286 287 and anaerobic blood agar (5% defibrinated sheep blood; blood agar base, 40 g/L; agar, 5 g/L; hemin, 10 mL/L; menadione, 5 drops/L. After sowing in solid media, the 288 289 swab will be inoculated in thioglycolate medium, where it will remain for 14 days. One 290 of the plates will be incubated in a capnophilic atmosphere (5% to 10% CO₂), while 291 the other will be incubated in strict anaerobiosis (atmosphere containing 10%) 292 CO₂,10% H₂, and 80% N₂) using an anaerobic chamber or Glove Box (Coy Labs[®], 293 USA).

The plates will be read after 24 h of incubation and, in case of growth, the colonies will be identified. In the absence of growth, they will be incubated again, and a new reading will be performed after 72 h. The thioglycolate vials containing skin swabs will be kept in a bacteriological incubator (35°C to 37°C) for 14 days.

In a laboratory setting, the tubes containing disc fragments and muscle–ligament tissue will undergo vortexing (Even EVX2800-BI[®], Brazil) for 15 s. All tubes will be kept in a bacteriological incubator (35°C to 37°C) and, after 24 h, the first subculture will be carried out using a 100 µL bacteriological loop. An aliquot of the thioglycolate will be

302 taken and plated on blood agar and anaerobic blood agar. The first plate will be 303 incubated in a capnophilic atmosphere and the second in strict anaerobiosis using an anaerobic chamber or Glove Box (Coy Labs®, USA). The plates will be read after 24 304 305 h and the colonies will be identified in case of growth. In the absence of growth, they will be incubated again, and a new reading will be performed after 72 h. The same 306 procedure will be used for all thioglycolate vials (totaling six vials for each level 307 308 approached). Thioglycolate tubes containing the clinical specimens will be kept in an oven for 14 days. Subcultures will be carried out after 72 h and always every 3 days, 309 310 with the last subculture being carried out on the 14th day of incubation in the same solid culture medium and atmospheres used in the first 24 h. 311

312 Quality control of culture media

313 Sterile saline solution at 0.9% will be used to control the sterility of the culture medium 314 and *Pseudomonas aeruginosa* ATCC 27853 and *Bacteroides fragilis* ATCC 25285 315 strains to evaluate the recovery capacity of facultative microorganisms and strict 316 anaerobes. Each new batch of culture medium prepared will undergo this quality 317 control.

318 **Phenotypic characterization**

The phenotypic identification of the species will be carried out through mass spectrometry using MALDI-TOF MS equipment (Bruker Biotyper[®], Germany). The score used for reliable identification of pathogens will follow the manufacturer's instructions.

323 Genotypic characterization

The microorganisms isolated from cultures will be subjected to PCR analysis performed in two phases, as described by Bernard et al. (28) The first to confirm the presence of bacteria (target and non-target) by using species-specific primers targeting the rRNA-16s and a second one, Multiplex_PCR, targeting the virulence and oxidative gens.

329 Multiomic Analyses

330 Whole Genome Sequencing

For the WGS, the DNA of the isolated *C. acnes* strains will be obtained with the Qiagen
Blood & Tissue DNA extraction kit (Qiagen[®], USA) and subsequent sample purification
using RNase.

334

335 The extracted and purified DNA will be dosed, and adjusted to a concentration of 0.2 ng/µL. The ends of its two ribbons will be fragmented and tagged (forward and reverse 336 5'--3'). This will form fragments of different sizes. This data will be used to create a 337 338 database on the Nextera Flex Kit platform (Ilumina[®], USA). The samples will then be multiplexed into a cell stream and run on the NextSeg sequencer (Ilumina[®], USA) 339 340 using paired sequencing to generate files in fastg format files, which will then be filtered 341 using the Trimmomatic tool version 0.36, as recommended by Bolger et al.(54) This step will be critical for controlling the quality of the analysis because it reduces the 342 343 possibility of errors during sequencing and allows the use of more reliable reading 344 codes.

345

The obtained fragments will be sequenced, and their quality will be evaluated with the FastQC tool version 0.11.9. The RedDog software version 1.11 will be used to identify single nucleotide polymorphisms (SNPs) using the GCA_000008345.1 *C. acnes*

reference strain deposited in the GenBank NCBI
[https://www.ncbi.nlm.nih.gov/nuccore/] as a comparison. Finally, the PATRIC
software version 3.5.21 will be used to create a complete genome phylogeny from the
concatenation of SNPs.

353 **Proteomics**

In this study, proteomics approaches will apply gel-free and in-gel protein digestion by using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) technique and (2)

357

358 Thioglycolate culture mediums will be centrifuged, and the sediment obtained will be washed in phosphate buffer and centrifuged again. The sediment will be dissolved in 359 a lysis solution containing 8 M urea, 2% 3-[(3-cholamidopropyl) dimethylammonio]-1-360 361 propanesulfonate, and 40 mM Tris (hydroxymethyl) aminomethane. This lysis will be 362 complemented with the use of glass beads under a Bead Beater agitation (Biospec Product[®], USA) (3 × 20 s with intervals of 20 s) followed by cooling for 5 min on an ice 363 364 bath, as described by Shah et al.(55) Protein concentration will be measured and 20 365 µg will be used for both the gel and solution techniques.

366

The SDS-PAGE -based technique will be used to evaluate the profile of the proteins present in the extract. Proteins will be removed from the gel with a sterile scalpel, eluted, and trypsinized (proteolic digestion) for further analysis through mass spectrometry. In the solution technique, the obtained extract will be trypsinized for further analysis through mass spectrometer. Regardless of the technique used, a nano-Liquid Chromatography coupled to a high-resolution mass spectrometer (nLC-HRMS) will be used.

374

375 After analysis by both techniques, the raw data (.raw) will be converted into a mascot general file (.mgf) using the Mascot Distiller software version 2.8.0, and proteins will 376 377 be identified using protein banks referring to *C. acnes* and eukaryotes (humans), both created using the NCBI as a *fasta* extension. After this identification, the data will be 378 379 validated using the Scaffold software version 5 for the same databases. Two biological 380 replicas will be made for both the gel and solution technique. The Interactivenn.net 381 [http://www.interactivenn.net/index.html](56) and STRING version 11 software (57) 382 will be used for comparative analysis and functional interaction of proteins, 383 respectively.

384 Metabolomics

The metabolomic analysis in this study will use intervertebral disc fragments with and 385 386 without isolated C. acnes. The tubes containing the disc fragments in thioglycolate 387 liquid culture medium will be centrifuged and the sediment will be transferred to 2 mL 388 flat-bottom polypropylene tubes containing a titanium bead (one per tube). The liquid 389 content of these tubes will be evaporated by centrifugation with the CentriVap 390 SpeedVac apparatus (Labconco Corporation[®], USA) and then weighed to determine the dry weight. The tubes will then have 500 µL of MS Grade (Fluka) acetonitrile added 391 392 followed by Bead Beater agitation (Biospec Product[®], USA) (4 x 30 s). When all the 393 material has been dissolved, the tubes will be centrifuged, and the supernatant will be 394 stored at -80°C in new sterile tubes. To identify the metabolites, the material will be 395 injected into a high-resolution mass spectrometer (UHPLC Q-TOF MS/MS). The data 396 obtained will be analyzed the Metaboanalyst 5.0 database in 397 [https://www.metaboanalyst.ca/] and its functions and interactions in the STRING 398 software version 11.(57)

399 **Questionnaires**

400 Questionnaires on pain (VNS), functionality (ODI), and quality of life (EQ-5D) will be 401 given at recruitment as well as at 1, 3, and 6 months postoperatively. A professional 402 who is not involved in the study will collect all questionaires. Follow-up clinical visits 403 will be carried out at 1, 3, and 6 months postoperatively, with acceptance deviation of 404 7, 14, and 21 days, respectively.

405 Imaging Studies

406 Imaging studies include 1.5 T magnetic resonance imaging. The tests must be dated no later than 6 months prior to the participant's inclusion in the study. Any of the 407 408 following changes will be considered disc degeneration: disc protrusion, extrusion, or 409 sequestration; reduced disc intensity; annular ruptures; Schmorl's nodes (Depressions on the surface of the vertebral bodies identified on MRI scans that result from the 410 411 pressure exerted by the intervertebral discs on the endplates, causing intervertebral 412 disc tissue herniation and displacement into the adjacent vertebral bodies); Modic 413 changes; and/or loss of disc height.

414 Modic Changes

The presence of Modic type 1 changes will be considered in the evaluation of magnetic resonance images. This change is characterized by the presence of a high signal on T2-weighted sequences, with reduced signal on T1-weighted sequences.(1,2) The frequency of Modic type 1 changes in the participants will be calculated for each of the research groups (presence or absence of colonization) and for the total number of discs analyzed in the laboratory.

422 Pfirrmann Classification

- 423 Degenerative changes identified in the discs will be categorized according to the
- 424 Pfirrmann classification(58) using T2-weighted magnetic resonance images.

425 **Confounding Variables**

- 426 As some of this information may change during the study, the data obtained at the
- time of inclusion in the study will be considered. Below are the confounding variables
- 428 to be analyzed:

429	٠	Age
430	•	Sex
431	٠	Education
432	•	Leave of absence
433	•	Alcohol consumption
434		 None or sporadically (< 1 dose/day)
435		2. Mild (1–2 doses/day)
436		Moderate/High (≥ 3 doses/day)
437	•	Smoking
438		1. Non-smoker
439		2. Smoker
440		3. Ex-smoker
441	٠	Body mass index
442		1. Underweight (< 18.5 Kg/m ²)
443		2. Normal (18.5–25 Kg/m ²)
444		3. Overweight (25–30 Kg/m ²)
445		4. Obese (> 30 Kg/m ²)
446	٠	Physical activity practice
447		1. Sedentary (not performing physical activity for at least 10 continuous
448		minutes during the week)
449		2. Active (vigorous activities for three or more days/week and for 20 min or
450		more per session; or moderate activity or walking for five or more
451		days/week and for 30 min or more per session; or any activity added
452		together 5 or more days/week and 150 min or more/week)
453		3. Very active (vigorous activity for five or more days/week and 30 min or
454		more per session; vigorous activity for three or more days/week and 20
455		min or more per session, more moderate activity and/or walking for five
456		or more days/week and for 30 min or more per session)

- Use of oral steroids up to 3 months before surgery
- Diabetes

459 Statistical planning

460 Sample size calculation

461 Considering the main outcome proposed, the identification of disc colonization by *C*. 462 *acnes*, the minimum sample size (n) for the population of interest will be 96 463 participants, according to the calculation described by Medronho et al.,(59) using a 464 confidence interval of 95% and a maximum margin of error of 10%.

The ideal sample size for analysis of secondary outcomes will depend on the incidence of the main outcome. If it is too low, an increase in the number of patients included will be performed with the inclusion of more blocks of participants. In order to have a more accurate dimension, the sample size calculation will be revised as soon as we reach half of the initially planned sample size.

470 Statistical analysis methodology

471 The database will be analyzed using the SPSS software, version 22.0, and R software, 472 version 4.0.2. Descriptive analysis will be performed by charts and descriptive statistics. The inferential analysis will consider a maximum significance level of 5%. 473 474 The chi-square test or Fisher's exact test will be used for inferential analysis of the distributions of categorical variables. The odds ratio (OR) will be the measure used to 475 estimate risk. The OR's significance will be evaluated by the OR's asymptotic 476 477 confidence interval. The hypothesis of normality will be verified by the Kolmogorov-Smirnov and Shapiro–Wilk tests. Student's t-test or Mann-Whitney test will be used in 478 479 the comparison of the two independent groups. More than two independent groups will be compared by the ANOVA or by the Kruskal–Wallis test. Two repeated measures 480 481 in different assessments will be compared by the paired Student's t-test or by the 482 Wilcoxon's signed-rank test. More than two repeated measures will be compared by 483 the ANOVA for repeated measures, or by the Friedman's test.

The identification of an optimal cutoff point for the marker associated with an outcome will be established through the analysis of the receiver operating characteristic (ROC) curve. The performance will be evaluated by the area under the ROC curve (AUC), and the significance of the AUC will be evaluated by the test that judges the null hypothesis that AUC is equal to 0.5. In addition to the significance test, the asymptotic confidence interval for the AUC will be obtained.

Analysis of the association between two quantitative variables will be visualized by scatter plots and quantified by the Pearson correlation coefficient, in the case of normal distributions, or by the Spearman's correlation coefficient, if normal distribution is not verified in at least one of the variables. The significance of the correlation coefficient will be evaluated by the correlation coefficient test. 495 Linear or non-linear regression models will be proposed to explain the relationship between the clinical-radiological variables of the patient and the quantitative outcome 496 variables (colonization and multiomic profile). For the variable colonization (binary), 497 498 logistic regression models will be proposed. Regression model parameters will be estimated by the maximum likelihood method, and the forward Wald method will be 499 used to choose the variables. The goodness of fit of the model will be analyzed by 500 501 adherence statistics, residual analysis, and verification of theoretical assumptions of 502 the model.

503 Ethics and dissemination

The protocol will follow the ethical standards of the HUGG REC. All patients whose biological materials will be analyzed will be well-informed of the research objectives and will sign ICF, agreeing with the availability of samples for further laboratory analysis.

508 Acknowledgements

The authors gratefully acknowledge the Brazilian agencies Conselho Nacional de Desenvolvimento Científico e Tecnologico (CNPq), Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) and the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) - Finance Code 001 for supporting this study.

514 Competing interests statement

515 The researchers declare no conflicts of interest.

517 Authors' contributions

VMR: conception and design of the work, data collection, data analysis and interpretation, and drafting the article. COGXL: conception and design of the work, data collection. EOF: conception and design of the work, data collection, data analysis and interpretation, critical revision of the article and final approval of the version to be published. GCF: electronic data storage. FCSN: data analysis and interpretation. LCMA: data analysis and interpretation. KMC: statistical design of the work, data analysis and interpretation. RKAF: critical revision of the article and final approval of the version to be published.

537 **References**

Modic MT, Masaryk TJ, Ross JS, Carter JR. Imaging of degenerative disk
 disease. Radiology [Internet]. 10 de julho de 1988 [citado 25 de julho de 2021];
 Disponível em: https://pubs.rsna.org/doi/abs/10.1148/radiology.168.1.3289089.

Modic MT, Steinberg PM, Ross JS, Masaryk TJ, Carter JR. Degenerative disk
 disease: assessment of changes in vertebral body marrow with MR imaging.
 Radiology. 10 de janeiro de 1988;166(1):193–9.

Tang G, Chen Y, Chen J, Wang Z, Jiang W. Higher proportion of low-virulence
 anaerobic bacterial infection in young patients with intervertebral disc herniation. Exp
 Ther Med. 2019/10/02 ed outubro de 2019;18(4):3085–9.

547 4. Capoor MN, Lochman J, McDowell A, Schmitz JE, Solansky M, Zapletalova M,
548 et al. Intervertebral disc penetration by antibiotics used prophylactically in spinal
549 surgery: implications for the current standards and treatment of disc infections. Eur
550 Spine J. 2018/12/07 ed abril de 2019;28(4):783–91.

551 5. Capoor MN, Ruzicka F, Machackova T, Jancalek R, Smrcka M, Schmitz JE, et 552 al. Prevalence of Propionibacterium acnes in Intervertebral Discs of Patients 553 Undergoing Lumbar Microdiscectomy: A Prospective Cross-Sectional Study. PLoS 554 One. 2016/08/19 ed 2016;11(8):e0161676.

555 Capoor MN, Konieczna A, McDowell A, Ruzicka F, Smrcka M, Jancalek R, et 6. 556 al. Pro-Inflammatory and Neurotrophic Factor Responses of Cells Derived from 557 Degenerative Human Intervertebral Discs to the Opportunistic Pathogen 558 Cutibacterium acnes. Int J Mol Sci [Internet]. 2021/03/04 ed 26 de fevereiro de 559 2021;22(5). Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/33652921

560 7. Capoor MN, Ruzicka F, Schmitz JE, James GA, Machackova T, Jancalek R, et 561 al. Propionibacterium acnes biofilm is present in intervertebral discs of patients 562 undergoing microdiscectomy. PLoS One. 2017/04/04 ed 2017;12(4):e0174518.

563 Schmid B, Hausmann O, Hitzl W, Achermann Y, Wuertz-Kozak K. The Role of 8. 564 Cutibacterium acnes in Intervertebral Disc Inflammation. Biomedicines [Internet]. 2020/07/08 565 ed 30 de junho de 2020;8(7). Disponível em: 566 https://www.ncbi.nlm.nih.gov/pubmed/32629986

9. Nguyen HP, Zaroff JG, Bayman EO, Gelb AW, Todd MM, Hindman BJ, et al.
Perioperative hypothermia (33 degrees C) does not increase the occurrence of
cardiovascular events in patients undergoing cerebral aneurysm surgery: findings from
the Intraoperative Hypothermia for Aneurysm Surgery Trial. Anesthesiology. agosto
de 2010;113(2):327–42.

Li B, Dong Z, Wu Y, Zeng J, Zheng Q, Xiao B, et al. Association Between
Lumbar Disc Degeneration and Propionibacterium acnes Infection: Clinical Research
and Preliminary Exploration of Animal Experiment. Spine Phila Pa 1976. 2015/12/15
ed 10 de julho de 2016;41(13):E764–9.

576 11. Yuan Y, Zhou Z, Jiao Y, Li C, Zheng Y, Lin Y, et al. Histological Identification
577 of Propionibacterium acnes in Nonpyogenic Degenerated Intervertebral Discs.
578 Biomed Res Int. 2017/04/13 ed 2017;2017:6192935.

579 12. Zheng Y, Lin Y, Chen Z, Jiao Y, Yuan Y, Li C, et al. Propionibacterium acnes 580 induces intervertebral discs degeneration by increasing MMP-1 and inhibiting TIMP-1 581 expression via the NF-kappaB pathway. Int J Clin Exp Pathol. 2018/07/01 ed 582 2018;11(7):3445–53.

583 13. Zhou Z, Chen Z, Zheng Y, Cao P, Liang Y, Zhang X, et al. Relationship between
584 annular tear and presence of Propionibacterium acnes in lumbar intervertebral disc.
585 Eur Spine J. 2015/08/20 ed novembro de 2015;24(11):2496–502.

14. Wang Y, Che M, Xin J, Zheng Z, Li J, Zhang S. The role of IL-1beta and TNFalpha in intervertebral disc degeneration. Biomed Pharmacother. 2020/08/28 ed
novembro de 2020;131:110660.

Albert HB, Sorensen JS, Christensen BS, Manniche C. Antibiotic treatment in
patients with chronic low back pain and vertebral bone edema (Modic type 1 changes):
a double-blind randomized clinical controlled trial of efficacy. Eur Spine J. abril de
2013;22(4):697–707.

16. Najafi S, Mahmoudi P, Bassampour SA, Shekarchi B, Soleimani M,
Mohammadimehr M. Molecular detection of Propionibacterium acnes in biopsy
samples of intervertebral disc with modic changes in patients undergoing herniated
disc surgery. Iran J Microbiol. dezembro de 2020;12(6):516–21.

597 17. Salehpour F, Aghazadeh J, Mirzaei F, Ziaeii E, Alavi SAN. Propionibacterium
598 acnes Infection in Disc Material and Different Antibiotic Susceptibility in Patients With
599 Lumbar Disc Herniation. Int J Spine Surg. 2019/05/28 ed abril de 2019;13(2):146–52.

Arndt J, Charles YP, Koebel C, Bogorin I, Steib JP. Bacteriology of degenerated
lumbar intervertebral disks. J Spinal Disord Tech. 2012/07/27 ed outubro de
2012;25(7):E211-6.

19. Stirling A, Worthington T, Rafiq M, Lambert PA, Elliott TSJ. Association
 between sciatica and Propionibacterium acnes. The Lancet. 2001;357(9273):2024–5.

Jiao Y, Lin Y, Zheng Y, Yuan Y, Chen Z, Cao P. The bacteria-positive proportion
in the disc tissue samples from surgery: a systematic review and meta-analysis. Eur
Spine J. 2019/07/18 ed dezembro de 2019;28(12):2941–50.

Rollason J, McDowell A, Albert HB, Barnard E, Worthington T, Hilton AC, et al.
Genotypic and antimicrobial characterisation of Propionibacterium acnes isolates from
surgically excised lumbar disc herniations. Biomed Res Int. 2013/09/26 ed
2013;2013:530382.

612 22. Carricajo A, Nuti C, Aubert E, Hatem O, Fonsale N, Mallaval FO, et al.
613 Propionibacterium acnes contamination in lumbar disc surgery. J Hosp Infect. julho de
614 2007;66(3):275–7.

Rigal J, Thelen T, Byrne F, Cogniet A, Boissiere L, Aunoble S, et al. Prospective
study using anterior approach did not show association between Modic 1 changes and
low grade infection in lumbar spine. Eur Spine J. 2016/01/29 ed abril de
2016;25(4):1000–5.

Urquhart DM, Zheng Y, Cheng AC, Rosenfeld JV, Chan P, Liew S, et al. Could
low grade bacterial infection contribute to low back pain? A systematic review. BMC
Med. 2015/01/23 ed 22 de janeiro de 2015;13:13.

Astur N, Martins DE, Wajchenberg M, Ferretti M, Menezes FG, Doi AM, et al.
Subclinical Propionibacterium acnes infection estimation in the intervertebral disc
(SPInE-ID): protocol for a prospective cohort. BMJ Open. 2017/11/21 ed 17 de
novembro de 2017;7(11):e017930.

626 26. Evangelopoulos DS, Stathopoulos IP, Morassi GP, Koufos S, Albarni A,
627 Karampinas PK, et al. Sonication: A Valuable Technique for Diagnosis and Treatment
628 of Periprosthetic Joint Infections. Sci World J. 10 de outubro de 2013;2013:e375140.

629 27. Suarez S, Nassif X, Ferroni A. [Applications of MALDI-TOF technology in 630 clinical microbiology]. Pathol Biol (Paris). fevereiro de 2015;63(1):43–52.

Barnard E, Nagy I, Hunyadkurti J, Patrick S, McDowell A. Multiplex touchdown
PCR for rapid typing of the opportunistic pathogen Propionibacterium acnes. J Clin
Microbiol. 2015/01/30 ed abril de 2015;53(4):1149–55.

Rajasekaran S, Tangavel C, Aiyer SN, Nayagam SM, Raveendran M, Demonte
NL, et al. ISSLS PRIZE IN CLINICAL SCIENCE 2017: Is infection the possible initiator
of disc disease? An insight from proteomic analysis. Eur Spine J. 2017/02/09 ed maio
de 2017;26(5):1384–400.

30. Rinschen MM, Ivanisevic J, Giera M, Siuzdak G. Identification of bioactive
metabolites using activity metabolomics. Nat Rev Mol Cell Biol. 2019/03/01 ed junho
de 2019;20(6):353–67.

Swank KR, Furness JE, Baker EA, Gehrke CK, Biebelhausen SP, Baker KC.
Metabolomic Profiling in the Characterization of Degenerative Bone and Joint
Diseases. Metabolites [Internet]. 2020/06/04 ed 29 de maio de 2020;10(6). Disponível
em: https://www.ncbi.nlm.nih.gov/pubmed/32485832

32. Ou J, Xiao M, Huang Y, Tu L, Chen Z, Cao S, et al. Serum Metabolomics
Signatures Associated With Ankylosing Spondylitis and TNF Inhibitor Therapy. Front
Immunol. 2021/03/09 ed 2021;12:630791.

648 33. Fernandez-Garcia M, Rojo D, Rey-Stolle F, Garcia A, Barbas C. Metabolomic649 Based Methods in Diagnosis and Monitoring Infection Progression. Exp Suppl.
650 2018/12/12 ed 2018;109:283–315.

34. Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and
towards mechanisms. Nat Rev Mol Cell Biol. 2016/03/17 ed julho de 2016;17(7):451–
9.

Shan L, Yang J, Meng S, Ruan H, Zhou L, Ye F, et al. Urine Metabolomics
Profiling of Lumbar Disc Herniation and its Traditional Chinese Medicine Subtypes in
Patients Through Gas Chromatography Coupled With Mass Spectrometry. Front Mol
Biosci. 2021/06/29 ed 2021;8:648823.

65836.Teckchandani S, Nagana Gowda GA, Raftery D, Curatolo M. Metabolomics in659chronic pain research. Eur J Pain. 2020/10/17 ed fevereiro de 2021;25(2):313–26.

Liu M, Xie Z, Costello CA, Zhang W, Chen L, Qi D, et al. Metabolomic analysis
coupled with extreme phenotype sampling identified that lysophosphatidylcholines are
associated with multisite musculoskeletal pain. Pain. 2020/08/25 ed 10 de fevereiro
de 2021;162(2):600–8.

664 38. Fujita N, Ishihara S, Michikawa T, Azuma K, Suzuki S, Tsuji O, et al. Potential
665 association of metabolic and musculoskeletal disorders with lumbar intervertebral disc
666 degeneration: Cross-sectional study using medical checkup data. J Orthop Sci.
667 2019/06/10 ed maio de 2020;25(3):384–8.

66839.Aroke EN, Powell-Roach KL. The Metabolomics of Chronic Pain Conditions: A669Systematic Review. Biol Res Nurs. 2020/07/16 ed outubro de 2020;22(4):458–71.

40. Ji RR, Donnelly CR, Nedergaard M. Astrocytes in chronic pain and itch. Nat Rev Neurosci. 2019/09/21 ed novembro de 2019;20(11):667–85. Wu X, Xiang H, Zhang G, Hu Y, wang yan, Chen B. A metabolic profiling
analysis of degenerative intervertebral disc disease in a rabbit model via GC/TOF-MS.
2019; Disponível em: https://www.researchsquare.com/article/rs-7971/v1

42. Radek M, Pacholczyk-Sienicka B, Jankowski S, Albrecht L, Grodzka M, Depta
A, et al. Assessing the correlation between the degree of disc degeneration on the
Pfirrmann scale and the metabolites identified in HR-MAS NMR spectroscopy. Magn
Reson Imaging. 2015/12/29 ed maio de 2016;34(4):376–80.

43. Teraguchi M, Yoshimura N, Hashizume H, Muraki S, Yamada H, Oka H, et al.
Metabolic Syndrome Components Are Associated with Intervertebral Disc
Degeneration: The Wakayama Spine Study. PLoS One. 2016/02/04 ed
2016;11(2):e0147565.

44. Veras MA, Lim YJ, Kuljanin M, Lajoie GA, Urquhart BL, Seguin CA. Protocol
for parallel proteomic and metabolomic analysis of mouse intervertebral disc tissues.
JOR Spine. 2020/10/06 ed setembro de 2020;3(3):e1099.

45. Tang G, Han X, Lin Z, Qian H, Chen B, Zhou C, et al. Propionibacterium acnes
Accelerates Intervertebral Disc Degeneration by Inducing Pyroptosis of Nucleus
Pulposus Cells via the ROS-NLRP3 Pathway. Oxid Med Cell Longev. 2021/02/20 ed
2021;2021:4657014.

46. Lin Y, Jiao Y, Yuan Y, Zhou Z, Zheng Y, Xiao J, et al. Propionibacterium acnes
induces intervertebral disc degeneration by promoting nucleus pulposus cell apoptosis
via the TLR2/JNK/mitochondrial-mediated pathway. Emerg Microbes Infect.
2018/01/13 ed 10 de janeiro de 2018;7(1):1.

694 47. Capoor MN, Ruzicka F, Sandhu G, Rollason J, Mavrommatis K, Ahmed FS, et
695 al. Importance of Propionibacterium acnes hemolytic activity in human intervertebral
696 discs: A microbiological study. PLoS One. 2018/11/30 ed 2018;13(11):e0208144.

48. Albert HB, Kjaer P, Jensen TS, Sorensen JS, Bendix T, Manniche C. Modic
changes, possible causes and relation to low back pain. Med Hypotheses.
2008;70(2):361–8.

49. Ohtori S, Koshi T, Yamashita M, Yamauchi K, Inoue G, Suzuki M, et al.
Existence of pyogenic spondylitis in Modic type 1 change without other signs of
infection: 2-year follow-up. Eur Spine J. 2010/03/10 ed julho de 2010;19(7):1200–5.

70350.Ritter PL, González VM, Laurent DD, Lorig KR. Measurement of pain using the704visual numeric scale. J Rheumatol. março de 2006;33(3):574–80.

51. Breivik H, Borchgrevink PC, Allen SM, Rosseland LA, Romundstad L, Hals EKB, et al. Assessment of pain. Br J Anaesth. julho de 2008;101(1):17–24.

52. Bagattini ÂM, Camey SA, Miguel SR, Andrade MV, de Souza Noronha KVM,
de C. Teixeira MA, et al. Electronic Version of the EQ-5D Quality-of-Life
Questionnaire: Adaptation to a Brazilian Population Sample. Value Health Reg Issues.
10 de dezembro de 2018;17:88–93.

53. Vigatto R, Alexandre NM, Correa Filho HR. Development of a Brazilian
Portuguese version of the Oswestry Disability Index: cross-cultural adaptation,
reliability, and validity. Spine Phila Pa 1976. 2007/02/17 ed 15 de fevereiro de
2007;32(4):481–6.

54. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina
sequence data. Bioinforma Oxf Engl. 10 de agosto de 2014;30(15):2114–20.

55. Lohse M, Bolger AM, Nagel A, Fernie AR, Lunn JE, Stitt M, et al. RobiNA: a
user-friendly, integrated software solution for RNA-Seq-based transcriptomics.
Nucleic Acids Res. julho de 2012;40 (Web Server issue):W622-627.

56. Shah H, Encheva V, Schmid O, Culak RA, Nasir P, Ines I, et al. Surface
Enhanced Laser Desorption/Ionization Time of Flight Mass Spectrometry (SELDITOF-MS): A Potentially Powerful Tool for Rapid Characterisation of Microorganisms.
In 2005. p. 57–95.

57. Heberle H, Meirelles GV, da Silva FR, Telles GP, Minghim R. InteractiVenn: a
web-based tool for the analysis of sets through Venn diagrams. BMC Bioinformatics.
22 de maio de 2015;16(1):169.

58. Urrutia J, Besa P, Campos M, Cikutovic P, Cabezon M, Molina M, et al. The Pfirrmann classification of lumbar intervertebral disc degeneration: an independent inter- and intra-observer agreement assessment. Eur Spine J. 2016/02/18 ed setembro de 2016;25(9):2728–33.

59. Medronho R, Bloch K, Luiz R, Werneck G. Epidemiologia. Atheneu. São Paulo.2009;

		STUDY PERIOD							
		Enrolment	Allocation		Close-out				
	TIMEPOINT**	Aug/22	Set/22	Oct/22	Dec/22	Feb/23	Apr/23	Jun/23	Aug/23
	ENROLMENT:								
	Eligibility screening	х		X					
	Informed consent			X					
medRxiv prep	Clinical Survey rint doi: https://doi.org/10.1101/2022.07.08	22277406; this version po	sted July 9, 2022. The cor	X yright holder f	or this preprin				
(which was	Images Evaluation	/funder, who has granted e under a CC-BY 4.0 Inter	nedRxiv a license to displ national license .	ay the preprint	in perpetuity.				
	Allocation		x						
	INTERVENTIONS:								
	Surgery								
	Sampling			-					
	Sample Analysis			+			→		
	ASSESSMENTS:								
	List baseline variables	X	X						
	Data processing				+			→	
	Publication preparation								X

*Recommended content can be displayed using various schematic formats. See SPIRIT 2013 Explanation and Elaboration for examples from protocols. **List specific timepoints in this row.

Fig 1



Fig 2